查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1454048

慢性咳嗽市場至2030年的預測：按藥物類別、給藥途徑、分銷管道、最終用戶和地區的全球分析

Chronic Cough Market Forecasts to 2030 - Global Analysis By Drug Class, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球慢性咳嗽市場規模為 73 億美元，預計在預測期內將以 10.0%的年複合成長率成長，到2030年達到 143 億美元。

根據大多數醫學定義，慢性咳嗽是指成人持續超過 8 週、兒童持續超過 4 週的持續性咳嗽。慢性咳嗽是一種症狀，而不是一種疾病，可能由多種潛在疾病引起，包括氣喘、過敏、胃食道逆流（GERD）、流鼻涕、吸菸、慢性支氣管炎和某些藥物。慢性咳嗽會對生活品質產生重大影響，可能需要進行醫學評估以確定根本原因和適當的治療。

印度2017年國家衛生政策目的是2025年將慢性咳嗽等非傳染性疾病造成的過早死亡率降低 25%。

慢性呼吸道疾病增加

市面上慢性呼吸道疾病的盛行率顯著上升。這種快速成長是由多種因素造成的，包括環境污染、生活方式的改變和人口老化。慢性呼吸道疾病越來越普遍，促進了市場的擴大。隨著人們所認知的提高和診斷技術的進步，對慢性呼吸道疾病有效治療方法的需求不斷增加，推動了該領域的進一步成長。

副作用和安全問題

慢性咳嗽藥物的常見副作用包括嗜睡、頭暈和胃腸道不適。潛在的藥物交互作用以及依賴和濫用某些藥物的風險也存在安全性問題。患有心血管或呼吸系統疾病等潛在疾病的患者的風險可能會增加。醫療保健提供者必須仔細評估每位患者的病歷並密切監測治療結果，以減輕這些擔憂。因此，這些都是限制市場成長的因素。

醫療保健支出增加

由於多種因素，包括診斷率的提高、患者數量的增加以及治療方法的進步，市場的醫療保健支出顯著成長。隨著意識的提高和更多患者尋求慢性咳嗽的治療，醫療費用繼續穩定增加。這一趨勢凸顯了將解決慢性咳嗽作為醫療保健優先事項的重要性，並強調需要繼續投資該細分市場的研發和患者照護工作。

昂貴的治療費用

慢性咳嗽市場應對治療成本上升的重大挑戰，對患者和醫療保健系統造成沉重負擔。與治療和持續管理相關的費用增加了尋求緩解這種持續性疾病的患者的經濟負擔。儘管醫療技術和治療方法取得了進步，但高昂的治療成本仍然是許多患者的治療障礙，迫切需要負擔得起且永續的醫療保健解決方案。

COVID-19 的影響：

COVID-19 大流行嚴重影響了慢性咳嗽市場，擾亂了診斷、治療和患者照護。封鎖措施、獲得醫療保健的機會減少以及優先分配資源來管理 COVID-19 導致慢性咳嗽的管理延誤。此外，由於害怕去醫療機構就診，患者不敢及時尋求治療。結果，診斷率和治療開始率下降，影響了市場成長。遠端醫療已成為首選的諮詢方法，在一定程度上緩解了限制，但它還無法完全取代現場評估。

減充血劑領域預計將成為預測期內最大的市場

由於人們對呼吸系統疾病的認知和盛行率不斷提高，鼻減充血劑市場預計在預測期內將成為最大的市場。它可以緩解鼻塞和鼻涕倒流，並解決持續咳嗽的根本原因。製藥公司積極從事研究和開發，以增強現有配方並推出新的鼻減充血劑。這種動態的市場情況證明了有效的減充血劑在治療慢性咳嗽和相關呼吸道疾病中的重要性。

預計醫院區隔在預測期內年複合成長率最高。

預計醫院區隔在預測期內年複合成長率最高。專門從事呼吸系統健康的大型醫院，包括著名的學術醫療中心和呼吸系統醫療設備，是主要參與者。這些醫院提供全面的服務，包括診斷影像、肺功能測試以及多學科專家團隊的服務。此外，提供尖端的治療方法和臨床試驗，以確保患者的慢性咳嗽症狀得到最佳的護理和管理。

佔有率最大的地區

預計北美在預測期內將佔據最大的市場佔有率。藥物療法，包括鎮咳藥和標靶治療，佔據市場主導地位。此外，針對新治療方法的研發活動的迅速增加進一步支持了市場擴張。市場以改善患者治療效果和生活品質為重點，不斷發展，並帶來充滿希望的創新和投資機會。

年複合成長率最高的地區：

由於污染程度上升、老年人口增加、生活方式改變導致呼吸系統疾病盛行率上升，以及對可用治療方案的認知不斷增強，預計亞太地區將在預測期內保持最高的年複合成長率。此外，人們對言語治療、呼吸練習和生活方式改變等非藥物干涉措施越來越感興趣。該地區各國的市場法律規範各不相同，影響著市場動態和產品供應。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球慢性咳嗽市場：依藥物類別

  • 抗生素
  • 酸阻斷劑
  • 皮質類固醇
  • 鼻減充血劑
  • 組合藥物
  • 抗組織胺藥
  • 其他藥物類別

第6章 全球慢性咳嗽市場：依給藥途徑分類

  • 吸入
  • 口服
  • 注射
  • 其他給藥途徑

第7章 全球慢性咳嗽市場：按分銷管道

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第8章 全球慢性咳嗽市場：依最終用戶分類

  • 專業中心
  • 居家照護
  • 醫院
  • 其他最終用戶

第9章 全球慢性咳嗽市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Teva Pharmaceuticals Industries
  • Mylan NV
  • Amneal Pharmaceuticals LLC
  • Novartis AG
  • Hikma Pharmaceuticals Plc
  • Bayer AG
  • GSK plc
  • Aurobindo Pharma
  • Apotex Inc.
  • Micro Labs Ltd
  • AstraZeneca plc
  • Sun Pharmaceuticals Industries Ltd
  • Cipla Limited
  • Glenmark Pharmaceuticals Ltd
  • NeRRe Therapeutics
  • Pfizer Inc.
Product Code: SMRC25600

According to Stratistics MRC, the Global Chronic Cough Market is accounted for $7.3 billion in 2023 and is expected to reach $14.3 billion by 2030 growing at a CAGR of 10.0% during the forecast period. A chronic cough is a persistent cough that lasts for more than eight weeks in adults or four weeks in children, according to most medical definitions. It's a symptom rather than a disease itself and can be caused by a variety of underlying conditions such as asthma, allergies, gastroesophageal reflux disease (GERD), postnasal drip, smoking, chronic bronchitis, or certain medications. Chronic cough can significantly impact quality of life and may require medical evaluation to determine the underlying cause and appropriate treatment.

According to the National Health Policy 2017, India, premature mortality due to non-communicable diseases, including chronic cough, will be reduced by ~ 25% by 2025.

Market Dynamics:

Driver:

Increasing prevalence of chronic respiratory diseases

The market is witnessing a notable rise in chronic respiratory diseases prevalence. This surge is attributed to various factors such as environmental pollution, lifestyle changes, and aging populations. Chronic respiratory conditions are increasingly prevalent, contributing to the expansion of the market. With growing awareness and diagnostic advancements, the demand for effective treatments for chronic respiratory ailments continues to escalate, driving further growth in this sector.

Restraint:

Side effects and safety concerns

Common side effects of pharmaceutical treatments for chronic cough include drowsiness, dizziness, and gastrointestinal disturbances. There are safety concerns regarding potential drug interactions and the risk of dependency or abuse with certain medications. Patients with underlying medical conditions such as cardiovascular issues or respiratory disorders may face heightened risks. It's imperative for healthcare providers to carefully assess each patient's medical history and closely monitor treatment outcomes to mitigate these concerns. Hence, these are the factors impeding the growth of the market.

Opportunity:

Rising healthcare expenditure

The market is witnessing a notable surge in healthcare expenditure, driven by various factors such as increased diagnosis rates, expanding patient populations, and advancements in treatment options. As awareness grows and more patients seek medical attention for chronic cough, healthcare spending continues to rise steadily. This trend underscores the significance of addressing chronic cough as a healthcare priority and highlights the need for continued investment in research, development, and patient care initiatives within this market segment.

Threat:

High cost of treatment

The market grapples with the significant challenge of high treatment costs, posing a considerable burden on patients and healthcare systems alike. The expenses associated with therapies and ongoing management contribute to financial strain for individuals seeking relief from this persistent condition. Despite advancements in medical technology and treatment modalities, the steep costs remain a barrier to access for many, underscoring the pressing need for affordable and sustainable solutions within the healthcare landscape.

Covid-19 Impact:

The COVID-19 pandemic significantly affected the Chronic Cough market, causing disruptions in diagnosis, treatment, and patient care. Lockdown measures, reduced healthcare access, and prioritization of resources towards managing COVID-19 led to delays in chronic cough management. Additionally, fear of visiting healthcare facilities deterred patients from seeking timely treatment. Consequently, there was a decline in diagnosis rates and treatment initiation, impacting market growth. Telemedicine emerged as a preferred mode for consultation, offering some relief amidst restrictions but couldn't fully compensate for in-person evaluations.

The decongestants segment is expected to be the largest during the forecast period

The decongestants segment is expected to be the largest during the forecast period driven by increasing awareness and prevalence of respiratory conditions. They alleviate nasal congestion and postnasal drip, addressing underlying causes of persistent coughing. Pharmaceutical companies actively engage in research and development to enhance existing formulations and introduce novel decongestant products. This dynamic market landscape underscores the importance of effective decongestants in managing chronic cough and related respiratory ailments.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Leading hospitals specializing in respiratory health, such as renowned academic medical centers and pulmonology departments, are crucial players. These hospitals offer comprehensive services, including diagnostic imaging, pulmonary function testing, and access to multidisciplinary teams of specialists. Additionally, they provide cutting-edge therapies and clinical trials, ensuring patients receive optimal care and management for their chronic cough conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Pharmaceutical interventions, including antitussive medications and targeted therapies, dominate the market landscape. Additionally, a surge in research and development activities aimed at novel treatment modalities further propels market expansion. With a focus on improving patient outcomes and quality of life, the market continues to evolve with promising opportunities for innovation and investment.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to increasing pollution levels, rising geriatric population, changing lifestyles leading to higher incidence of respiratory diseases, and growing awareness about available treatment options. Additionally, there was growing interest in non-pharmacological interventions such as speech therapy, breathing exercises, and lifestyle modifications. Regulatory frameworks governing the market varied across countries in the region, influencing market dynamics and product availability.

Key players in the market

Some of the key players in Chronic Cough market include Teva Pharmaceuticals Industries, Mylan N.V., Amneal Pharmaceuticals LLC, Novartis AG, Hikma Pharmaceuticals Plc, Bayer AG, GSK plc, Aurobindo Pharma, Apotex Inc., Micro Labs Ltd, AstraZeneca plc, Sun Pharmaceuticals Industries Ltd, Cipla Limited, Glenmark Pharmaceuticals Ltd, NeRRe Therapeutics and Pfizer Inc.

Key Developments:

In September 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired ASX-listed digital health startup ResApp Health for $115 million. With this acquisition, Pfizer aimed to enhance its product portfolio and expand its presence in crucial healthcare technology areas.

In January 2022, Merck announced Gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of patients with RCC or unexplained chronic cough (UCC), was approved by FDA.

Drug Classes Covered:

  • Antibiotics
  • Acid Blockers
  • Corticosteroids
  • Decongestants
  • Combination Drug
  • Antihistamines
  • Other Drug Classes

Route of Administrations Covered:

  • Inhalational
  • Oral
  • Injectable
  • Other Route of Administrations

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

End Users Covered:

  • Speciality Centres
  • Homecare
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Chronic Cough Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Antibiotics
  • 5.3 Acid Blockers
  • 5.4 Corticosteroids
  • 5.5 Decongestants
  • 5.6 Combination Drug
  • 5.7 Antihistamines
  • 5.8 Other Drug Classes

6 Global Chronic Cough Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Inhalational
  • 6.3 Oral
  • 6.4 Injectable
  • 6.5 Other Route of Administrations

7 Global Chronic Cough Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacy
  • 7.3 Hospital Pharmacy
  • 7.4 Online Pharmacy

8 Global Chronic Cough Market, By End User

  • 8.1 Introduction
  • 8.2 Speciality Centres
  • 8.3 Homecare
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Chronic Cough Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Teva Pharmaceuticals Industries
  • 11.2 Mylan N.V.
  • 11.3 Amneal Pharmaceuticals LLC
  • 11.4 Novartis AG
  • 11.5 Hikma Pharmaceuticals Plc
  • 11.6 Bayer AG
  • 11.7 GSK plc
  • 11.8 Aurobindo Pharma
  • 11.9 Apotex Inc.
  • 11.10 Micro Labs Ltd
  • 11.11 AstraZeneca plc
  • 11.12 Sun Pharmaceuticals Industries Ltd
  • 11.13 Cipla Limited
  • 11.14 Glenmark Pharmaceuticals Ltd
  • 11.15 NeRRe Therapeutics
  • 11.16 Pfizer Inc.

List of Tables

  • Table 1 Global Chronic Cough Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 4 Global Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 5 Global Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 6 Global Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 7 Global Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 8 Global Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 9 Global Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 10 Global Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 11 Global Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 12 Global Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 13 Global Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 14 Global Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 15 Global Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 16 Global Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 17 Global Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 18 Global Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 19 Global Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 21 Global Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 22 Global Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 26 North America Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 27 North America Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 28 North America Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 29 North America Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 30 North America Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 31 North America Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 32 North America Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 33 North America Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 34 North America Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 35 North America Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 36 North America Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 37 North America Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 38 North America Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 39 North America Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 40 North America Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 41 North America Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 42 North America Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 North America Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 44 North America Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 45 North America Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 49 Europe Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 50 Europe Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 51 Europe Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 52 Europe Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 53 Europe Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 54 Europe Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 55 Europe Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 56 Europe Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 57 Europe Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 58 Europe Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 59 Europe Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 60 Europe Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 61 Europe Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 62 Europe Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 63 Europe Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 64 Europe Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 65 Europe Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Europe Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 67 Europe Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 68 Europe Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 Europe Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 72 Asia Pacific Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 73 Asia Pacific Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 74 Asia Pacific Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 75 Asia Pacific Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 76 Asia Pacific Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 77 Asia Pacific Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 78 Asia Pacific Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 79 Asia Pacific Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 80 Asia Pacific Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 81 Asia Pacific Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 82 Asia Pacific Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 83 Asia Pacific Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 84 Asia Pacific Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 85 Asia Pacific Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 86 Asia Pacific Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 87 Asia Pacific Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 88 Asia Pacific Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 89 Asia Pacific Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 90 Asia Pacific Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 91 Asia Pacific Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 92 Asia Pacific Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 95 South America Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 96 South America Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 97 South America Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 98 South America Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 99 South America Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 100 South America Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 101 South America Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 102 South America Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 103 South America Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 104 South America Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 105 South America Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 106 South America Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 107 South America Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 108 South America Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 109 South America Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 110 South America Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 111 South America Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 112 South America Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 113 South America Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 114 South America Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 115 South America Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 118 Middle East & Africa Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 119 Middle East & Africa Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 120 Middle East & Africa Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 121 Middle East & Africa Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 122 Middle East & Africa Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 123 Middle East & Africa Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 124 Middle East & Africa Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 125 Middle East & Africa Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 126 Middle East & Africa Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 127 Middle East & Africa Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 128 Middle East & Africa Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 129 Middle East & Africa Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 130 Middle East & Africa Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 131 Middle East & Africa Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 132 Middle East & Africa Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 133 Middle East & Africa Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 134 Middle East & Africa Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 135 Middle East & Africa Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 136 Middle East & Africa Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 137 Middle East & Africa Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 138 Middle East & Africa Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)